REMEGEN
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
REMEGEN
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Status:
Active
Contact:
(86) 535-6113513
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Apache PHP Apache 2.2 Alibaba Alibaba Cloud MailBox Win32 Header Apache Tomcat JK AliDNS
Similar Organizations
MabSpace Biosciences
MabSpace Biosciences is a biotech company focused on discovery & development of innovative antibody based therapeutics for cancer.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Lilly Asia Ventures
Lilly Asia Ventures investment in Private Equity Round - Remegen
Vivo Capital
Vivo Capital investment in Private Equity Round - Remegen
Lake Bleu Capital
Lake Bleu Capital investment in Private Equity Round - Remegen
China Reform Fund Management
China Reform Fund Management investment in Private Equity Round - Remegen
Janchor Partners
Janchor Partners investment in Private Equity Round - Remegen
OrbiMed
OrbiMed investment in Private Equity Round - Remegen
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Private Equity Round - Remegen
Loyal Valley Capital
Loyal Valley Capital investment in Private Equity Round - Remegen
Shenzhen Capital Group
Shenzhen Capital Group investment in Private Equity Round - Remegen
Lapam Capital
Lapam Capital investment in Private Equity Round - Remegen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-19 | Biocytogen | Remegen investment in Post-IPO Equity - Biocytogen | 49.8 M USD |